Identification of a novel scaffold for allosteric inhibition of wild type and drug resistant HIV-1 reverse transcriptase by fragment library screening

Journal of Medicinal Chemistry

Volumn 54, Issue 3, 2011, Pages 699-708

  Geitmann, Matthis ^a   Elinder, Malin ^b   Seeger, Christian ^a,b   Brandt, Peter ^a   De Esch, Iwan J P ^c   Danielson, U Helena ^a,b  

^a Beactica   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME VARIANT; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SCAFFOLD PROTEIN;

ANALYSIS; ARTICLE; BINDING SITE; BIOSENSOR; ENZYME INHIBITION; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; IMMUNE DEFICIENCY; NONHUMAN; SCREENING; WILD TYPE;

ALLOSTERIC REGULATION; ANTI-HIV AGENTS; BINDING SITES; BIOSENSING TECHNIQUES; DATABASES, FACTUAL; DRUG RESISTANCE, VIRAL; ENZYME ASSAYS; HIGH-THROUGHPUT SCREENING ASSAYS; HIV REVERSE TRANSCRIPTASE; HIV-1; REVERSE TRANSCRIPTASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79851493846     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm1010513     Document Type: Article

References (32)

1. Broder, S. The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. Antiviral Res. 2010, 85, 1-18.
2. Ren, J.; Stammers, D. K. HIV reverse transcriptase structures: designing new inhibitors and understanding mechanisms of drug resistance. Trends Pharmacol. Sci. 2005, 26, 4-7. (Pubitemid 40052701)
3. Ren, J.; Esnouf, R.; Hopkins, A.; Ross, C.; Jones, Y.; Stammers, D.; Stuart, D. The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: lessons for inhibitor design. Structure 1995, 3, 915-926.
4. Spence, R. A.; Kati, W. M.; Anderson, K. S.; Johnson, K. A. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science 1995, 267, 988-993.
5. Kohlstaedt, L. A.; Wang, J.; Friedman, J. M.; Rice, P. A.; Steitz, T. A. Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 1992, 256, 1783-1790.
6. Hajduk, P. J.; Greer, J. A decade of fragment-based drug design: strategic advances and lessons learned. Nat. Rev. Drug Discovery 2007, 6, 211-219. (Pubitemid 46344625)
7. De Kloe, G. E.; Bailey, D.; Leurs, R.; de Esch, I. J. Transforming fragments into candidates: small becomes big in medicinal chemistry. Drug Discovery Today 2009, 14, 630-646.
8. Danielson, U. H. Fragment library screening and lead characterization using SPR biosensors. Curr. Top. Med. Chem. 2009, 9, 1725-1735.
9. Danielson, U. H. Integrating surface plasmon resonance biosensor-based interaction kinetic analyses into the lead discovery and optimization process. Future Med. Chem. 2009, 1, 1399-1414.
10. Brandt, P.; Geitmann, M.; Danielson, U. H. Deconstruction of non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1 for exploration of the optimization landscape of fragments. J. Med. Chem. DOI: 10.1021/jm101052g.
11. Geitmann, M.; Unge, T.; Danielson, U. H. Biosensor-based kinetic characterization of the interaction between HIV-1 reverse transcriptase and non-nucleoside inhibitors. J. Med. Chem. 2006, 49, 2367-2374.
12. Geitmann, M.; Unge, T.; Danielson, U. H. Interaction kinetic characterization of HIV-1 reverse transcriptase non-nucleoside inhibitor resistance. J. Med. Chem. 2006, 49, 2375-2387.
13. Nordström, H.; Gossas, T.; Hämäläinen, M.; Källblad, P.; Nyström, S.; Wallberg, H.; Danielson, U. H. Identification of MMP-12 inhibitors by using biosensor-based screening of a fragment library. J. Med. Chem. 2008, 51, 3449-3459. (Pubitemid 351875001)
14. Tversky, A. Features of similarity. Psychol. Rev. 1977, 84, 327-352.
15. Liu, T.; Lin, Y.; Wen, X.; Jorissen, R. N.; Gilson, M. K. BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities. Nucleic Acids Res. 2007, 35, D198-201. (Pubitemid 46056198)
16. Elinder, M.; Geitmann, M.; Gossas, T.; Källblad, P.; Winquist, J.; Nordström, H.; Hämäläinen, M.; Danielson, U. H. Experimental validation of a fragment library for lead discovery using SPR biosensor technology. J. Biomol. Screening, in press.
17. Hopkins, A. L.; Groom, C. R.; Alex, A. Ligand efficiency: a useful metric for lead selection. Drug Discovery Today 2004, 9, 430-431. (Pubitemid 38510559)
18. Reynolds, C. H.; Bembenek, S. D.; Tounge, B. A. The role of molecular size in ligand efficiency. Bioorg. Med. Chem. Lett. 2007, 17, 4258-4261. (Pubitemid 47028600)
19. Hajduk, P. J. Fragment-based drug design: How big is too big? J. Med. Chem. 2006, 49, 6972-6976. (Pubitemid 44885985)
20. Proudfoot, J. R.; Hargrave, K. D.; Kapadia, S. R.; Patel, U. R.; Grozinger, K. G.; McNeil, D. W.; Cullen, E.; Cardozo, M.; Tong, L.; Kelly, T. A.; et al. Novel non-nucleoside inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase. 4. 2-Substituted dipyridodiazepinones as potent inhibitors of both wild-type and cysteine-181 HIV-1 reverse transcriptase enzymes. J. Med. Chem. 1995, 38, 4830-4838.
21. Xu, G.; Micklatcher, M.; Silvestri, M. A.; Hartman, T. L.; Burrier, J.; Osterling, M. C.; Wargo, H.; Turpin, J. A.; Buckheit, R. W., Jr.; Cushman, M. The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors. J. Med. Chem. 2001, 44, 4092-4113. (Pubitemid 33095318)
22. Mai, A.; Sbardella, G.; Artico, M.; Ragno, R.; Massa, S.; Novellino, E.; Greco, G.; Lavecchia, A.; Musiu, C.; La Colla, M.; Murgioni, C.; La Colla, P.; Loddo, R. Structure-based design, synthesis, and biological evaluation of conformationally restricted novel 2-alkylthio-6-[1-(2,6-difluorophenyl)alkyl]-3, 4-dihydro-5-alkylpyrimidin-4(3H)-ones as non-nucleoside inhibitors of HIV-1 reverse transcriptase. J.Med. Chem. 2001, 44, 2544-2554. (Pubitemid 32852144)
23. Saari, W. S.; Hoffman, J. M.; Wai, J. S.; Fisher, T. E.; Rooney, C. S.; Smith, A. M.; Thomas, C. M.; Goldman, M. E.; O'Brien, J. A.; Nunberg, J. H.; et al. 2-Pyridinone derivatives: a new class of nonnucleoside, HIV-1-specific reverse transcriptase inhibitors. J. Med. Chem. 1991, 34, 2922-2925.
24. Silvestri, R.; De Martino, G.; La Regina, G.; Artico, M.; Massa, S.; Vargiu, L.; Mura, M.; Loi, A. G.; Marceddu, T.; La Colla, P. Novel indolyl aryl sulfones active against HIV-1 carrying NNRTI resistance mutations: synthesis and SAR studies. J. Med. Chem. 2003, 46, 2482-2493. (Pubitemid 36637932)
25. Dolle, V.; Nguyen, C. H.; Legraverend, M.; Aubertin, A. M.; Kirn, A.; Andreola, M. L.; Ventura, M.; Tarrago-Litvak, L.; Bisagni, E. Synthesis and antiviral activity of 4-benzyl pyridinone derivatives as potent and selective non-nucleoside human immunodeficiency virus type 1 reverse transcriptase inhibitors. J. Med. Chem. 2000, 43, 3949-3962.
26. Elinder, M.; Selhorst, P.; Vanham, G.; Öberg, B.; Vrang, L.; Danielson, U. Inhibition of HIV-1 by non-nucleoside reverse transcriptase inhibitors via an induced fit mechanism. Importance of slow dissociation and relaxation rates for antiviral efficacy. Biochem. Pharmacol. 2010, 80, 1133-1140.
27. Kwong, A. D.; McNair, L.; Jacobson, I.; George, S. Recent progress in the development of selected hepatitis C virus NS3.4A protease and NS5B polymerase inhibitors. Curr. Opin. Pharmacol. 2008, 8, 522-531.
28. Xia, Q.; Radzio, J.; Anderson, K. S.; Sluis-Cremer, N. Probing nonnucleoside inhibitor-induced active-site distortion in HIV-1 reverse transcriptase by transient kinetic analyses. Protein Sci. 2007, 16, 1728-1737. (Pubitemid 47195699)
29. de Kloe, G. E.; Retra, K.; Geitmann, M.;Källblad, P.; Smit, A. B.; van Muijlwijk-Koezen, J. E.; Leurs, R.; Irth, H.; Danielson, U. H.; De Esch, I. J. P. Surface plasmon resonance biosensor based fragment screening using acetylcholine binding protein identifies ligand efficiency hot spots (LE hot spots) by deconstruction of nicotinic acetylcholine receptor alpha7 ligands. J. Med. Chem. 2010, 53, 7192-7201.
30. Sastry, M.; Lowrie, J. F.; Dixon, S. L.; Sherman, W. Large-scale systematic analysis of 2D fingerprint methods and parameters to improve virtual screening enrichments. J. Chem. Inf. Model. 2010, 50, 771-784.
31. de Bethune, M. P. Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009). Antiviral Res. 2010, 85, 75-90.
32. Elinder, M.; Nordström, H.; Geitmann, M.; Hämäläinen, M.; Vrang, L.; Öberg, B.; Danielson, U. H. Screening for NNRTIs with slow dissociation and high affinity for a panel of HIV-1 RT variants. J. Biomol. Screening 2009, 14, 395-403.